(VNDA) Vanda Pharmaceuticals - Overview
Stock: Sleep-Wake, Antipsychotic, Immunology, Oncology
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 63.7% |
| Relative Tail Risk | -22.4% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.96 |
| Alpha | 49.77 |
| Character TTM | |
|---|---|
| Beta | 0.535 |
| Beta Downside | 0.576 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.19% |
| CAGR/Max DD | 0.03 |
Description: VNDA Vanda Pharmaceuticals December 31, 2025
Vanda Pharmaceuticals (NASDAQ: VNDA) is a U.S.-based biopharma that commercializes therapies for high-unmet-need conditions, currently selling HETLIOZ for non-24-hour sleep-wake disorder, Fanapt (iloperidone) for bipolar I and Parkinson’s disease psychosis (with a long-acting injectable under development), and Ponvory for psoriasis and ulcerative colitis.
The pipeline expands the sleep-disorder franchise (HETLIOZ for jet-lag, insomnia, delayed-sleep-phase disorder, autism-related sleep disturbances, and pediatric Non-24) and adds new modalities: a Fanapt LAI for schizophrenia, Bysanti for acute bipolar I, schizophrenia and major depressive disorder, Tradipitant for gastroparesis/motion sickness/atopic dermatitis, Imsidolimab (IL-36R antagonist) for generalized pustular psoriasis, VTR-297 (HDAC inhibitor) for hematologic malignancies, and VQW-765 (nicotinic receptor partial agonist) for performance anxiety. Ancillary programs include CFTR modulators (e.g., VSJ-110 for dry eye), antisense oligonucleotides for Charcot-Marie-Tooth disease, and a polycythemia-vera candidate (VGT-1849A).
As of the most recent 10-Q, VNDA reported $115 million in total revenue (≈ 70 % derived from HETLIOZ), a cash runway of roughly $250 million, and R&D spending of $55 million, reflecting a 48 % YoY increase in pipeline investment. The sleep-disorder market is projected to grow at a 6-7 % CAGR through 2028, driven by rising prevalence of circadian-rhythm disorders and expanding diagnostic awareness-key tailwinds for Vanda’s core assets. Moreover, the broader biotechnology sector benefits from a low-interest-rate environment that sustains high valuations for companies with differentiated, niche-focused product lines.
For a deeper dive into VNDA’s valuation metrics and peer comparison, the ValueRay platform offers a concise, data-driven snapshot.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -84.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.14 > 0.02 and ΔFCF/TA -10.98 > 1.0 |
| NWC/Revenue: 117.7% < 20% (prev 179.9%; Δ -62.16% < -1%) |
| CFO/TA -0.14 > 3% & CFO -81.8m > Net Income -84.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.9m) vs 12m ago 1.05% < -2% |
| Gross Margin: 93.61% > 18% (prev 0.92%; Δ 9269 % > 0.5%) |
| Asset Turnover: 34.03% > 50% (prev 29.59%; Δ 4.45% > 0%) |
| Interest Coverage Ratio: -77.37 > 6 (EBITDA TTM -101.5m / Interest Expense TTM -1.40m) |
Altman Z'' -1.79
| A: 0.42 (Total Current Assets 367.5m - Total Current Liabilities 117.9m) / Total Assets 601.1m |
| B: -0.42 (Retained Earnings -253.6m / Total Assets 601.1m) |
| C: -0.17 (EBIT TTM -108.5m / Avg Total Assets 623.1m) |
| D: -1.87 (Book Value of Equity -253.0m / Total Liabilities 135.1m) |
| Altman-Z'' Score: -1.79 = D |
Beneish M -2.82
| DSRI: 1.06 (Receivables 50.5m/42.8m, Revenue 212.1m/190.9m) |
| GMI: 0.98 (GM 93.61% / 91.64%) |
| AQI: 1.16 (AQ_t 0.37 / AQ_t-1 0.32) |
| SGI: 1.11 (Revenue 212.1m / 190.9m) |
| TATA: -0.00 (NI -84.2m - CFO -81.8m) / TA 601.1m) |
| Beneish M-Score: -2.82 (Cap -4..+1) = A |
What is the price of VNDA shares?
Over the past week, the price has changed by -2.97%, over one month by +2.46%, over three months by +69.91% and over the past year by +62.55%.
Is VNDA a buy, sell or hold?
- StrongBuy: 1
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the VNDA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.6 | 81.5% |
| Analysts Target Price | 13.6 | 81.5% |
| ValueRay Target Price | 8.9 | 18.9% |
VNDA Fundamental Data Overview February 10, 2026
P/S = 2.1095
P/B = 0.9613
P/EG = -2.42
Revenue TTM = 212.1m USD
EBIT TTM = -108.5m USD
EBITDA TTM = -101.5m USD
Long Term Debt = 10.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.27m USD (from shortTermDebt, last fiscal year)
Debt = 6.23m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -63.8m USD (from netDebt column, last quarter)
Enterprise Value = 159.8m USD (447.4m + Debt 6.23m - CCE 293.8m)
Interest Coverage Ratio = -77.37 (Ebit TTM -108.5m / Interest Expense TTM -1.40m)
EV/FCF = -1.93x (Enterprise Value 159.8m / FCF TTM -83.0m)
FCF Yield = -51.90% (FCF TTM -83.0m / Enterprise Value 159.8m)
FCF Margin = -39.11% (FCF TTM -83.0m / Revenue TTM 212.1m)
Net Margin = -39.70% (Net Income TTM -84.2m / Revenue TTM 212.1m)
Gross Margin = 93.61% ((Revenue TTM 212.1m - Cost of Revenue TTM 13.6m) / Revenue TTM)
Gross Margin QoQ = 94.75% (prev 91.47%)
Tobins Q-Ratio = 0.27 (Enterprise Value 159.8m / Total Assets 601.1m)
Interest Expense / Debt = 56.59% (Interest Expense 3.52m / Debt 6.23m)
Taxrate = 21.0% (US default 21%)
NOPAT = -85.8m (EBIT -108.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.12 (Total Current Assets 367.5m / Total Current Liabilities 117.9m)
Debt / Equity = 0.01 (Debt 6.23m / totalStockholderEquity, last quarter 466.0m)
Debt / EBITDA = 0.63 (negative EBITDA) (Net Debt -63.8m / EBITDA -101.5m)
Debt / FCF = 0.77 (negative FCF - burning cash) (Net Debt -63.8m / FCF TTM -83.0m)
Total Stockholder Equity = 500.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.51% (Net Income -84.2m / Total Assets 601.1m)
RoE = -16.82% (Net Income TTM -84.2m / Total Stockholder Equity 500.6m)
RoCE = -21.22% (EBIT -108.5m / Capital Employed (Equity 500.6m + L.T.Debt 10.9m))
RoIC = -17.13% (negative operating profit) (NOPAT -85.8m / Invested Capital 500.6m)
WACC = 7.78% (E(447.4m)/V(453.6m) * Re(7.89%) + (debt cost/tax rate unavailable))
Discount Rate = 7.89% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 1.16%
Fair Price DCF = unknown (Cash Flow -83.0m)
EPS Correlation: -63.77 | EPS CAGR: 6.73% | SUE: 4.0 | # QB: 1
Revenue Correlation: -51.19 | Revenue CAGR: -4.94% | SUE: -0.15 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.42 | Chg30d=+0.007 | Revisions Net=+1 | Analysts=3
EPS next Year (2026-12-31): EPS=-1.45 | Chg30d=+0.090 | Revisions Net=+3 | Growth EPS=+45.8% | Growth Revenue=+24.3%